Kopran Ltd has strengthened its leadership team with the appointment of Mr. Vijay L Thange as Chief Technical Officer (CTO). The appointment, effective June 26, 2026, places a seasoned industry veteran at the helm of the company's technical operations. This strategic move aims to leverage Mr. Thange's extensive expertise to drive operational excellence within the organization.

Mr. Thange brings over 36 years of experience in the pharmaceutical sector to his new role. His career spans significant tenures at major pharmaceutical companies, including Cipla and RPG Life Sciences. Prior to joining Kopran Ltd, he served as Vice President – Plant Operation at USV Limited, where he honed his skills in managing large-scale plant operations.

Executive Profile

The new CTO holds a robust academic background that complements his professional experience. His qualifications include a BSc, LLB, and a Post Graduate Diploma in Operations. Additionally, he has earned an MBA with a specialization in Operations Management, equipping him with the necessary theoretical and practical knowledge for his new responsibilities.

Appointment Details

The following table summarizes the key details regarding the new appointment:

As a full-time employee, Mr. Thange will be responsible for overseeing the company's technical functions and ensuring the efficient operation of its manufacturing facilities. His appointment is expected to bolster the company's operational capabilities as it continues to expand its market presence.

Kopran Ltd has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors, which met on May 19, 2026, approved the financial statements, recommended a dividend for the fiscal year, and made a key board appointment. Additionally, the company filed an investor presentation with the exchanges on May 20, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Q4 Performance Highlights

Kopran delivered a strong quarterly performance, with consolidated net profit for Q4 rising to ₹1,887 lakh compared to ₹968 lakh in the same quarter of the prior year. Revenue from operations for the quarter grew to ₹23,402 lakh from ₹17,236 lakh in the corresponding prior-year period. EBITDA for Q4 improved significantly to ₹4,057 lakh versus ₹1,400 lakh in Q4 of the prior year, with the EBITDA margin expanding to 17.34% from 8.12% year-on-year, indicating improved operational efficiency. The company achieved its highest ever quarterly revenue and EBITDA during this period.

The following table presents the key Q4 year-on-year comparisons on a consolidated basis:

Full-Year Financial Performance

For the financial year ended March 31, 2026, the company reported a consolidated net profit of ₹2,573.12 lakh, compared to ₹3,855.19 lakh in the previous year. Revenue from operations for the year increased to ₹68,142.36 lakh from ₹62,960.44 lakh in FY25. On a standalone basis, the net profit for the year was ₹3,039.97 lakh, up from ₹2,685.62 lakh in the prior year, while standalone revenue from operations rose to ₹30,564.62 lakh from ₹27,100.95 lakh in the previous year.

The following table summarizes the key financial figures for the consolidated and standalone results for the year ended March 31, 2026:

Dividend Declaration

The Board has recommended a dividend of ₹3.00 per equity share, representing 30% of the face value of ₹10 each. This dividend is subject to the approval of the shareholders at the forthcoming 67th Annual General Meeting.

Board Appointment

During the meeting, the Board appointed Mrs. Namrata Somani as an Additional Director (Non-Executive, Promoter Group) effective May 19, 2026. Her appointment is subject to shareholder approval and she is liable to retire by rotation.